Technology Description
The non-invasive prenatal screening method detects chromosomal aneuploidies in the fetus based on fragments of cell-free DNA released from the placenta into the mother’s blood. These free DNA fragments are extracted from the maternal serum and then sequenced. Next, these DNA fragments are aligned to the human reference genome to determine their origin. Afterward, by counting the number of free DNA fragments on the target chromosomes and comparing them to a set of normal pregnancies, the test can determine whether the fetus has the surveyed chromosomal aneuploidy. The kit screening 2,800 mutations related to 09 recessive diseases and over 30 single genes from cell free DNA.
Materials include in the kit
- Extracting cell-free DNA
- Library preparation
- Hybridization and capture specific DNA fragments for analysis
- Clean up kit
- Instruction of use
- Training process to use the kit
